Leniolisib

(Joenja®)

Leniolisib

Drug updated on 11/17/2023

Dosage FormTablet (oral: 70 mg)
Drug ClassKinase inhibitor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Joenja (leniolisib) Prescribing Information. 2023Pharming Group N.V., Leiden, The Netherlands

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines